Immunotherapy for hepatocellular carcinoma has risen to the forefront of research in recent years, and the main immunotherapy medications are immune checkpoint inhibitors, primarily programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1). Here, PDCD1 is linked to hepatocellular carcinoma.